Hims & Hers Health (NYSE:HIMS) Cut to Neutral at BTIG Research

Posted by Hanz Christensen on Feb 24th, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) was downgraded by stock analysts at BTIG Research from a “buy” rating to a “neutral” rating in a report issued on Tuesday.

A number of other equities analysts also recently weighed in on HIMS. Zacks Research downgraded Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on shares of Hims & Hers Health and gave the company a “hold” rating in a research note on Tuesday, February 10th. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Citigroup reduced their target price on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a report on Monday, February 9th. Finally, UBS Group set a $32.00 price target on shares of Hims & Hers Health in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average price target of $37.71.

View Our Latest Stock Analysis on HIMS

Hims & Hers Health Stock Down 1.0%

Shares of NYSE:HIMS opened at $15.47 on Tuesday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The company’s fifty day moving average is $28.21 and its two-hundred day moving average is $40.02. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of 28.64, a price-to-earnings-growth ratio of 2.92 and a beta of 2.43. Hims & Hers Health has a 1-year low of $15.15 and a 1-year high of $70.43.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. During the same quarter in the previous year, the firm posted $0.11 EPS. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. Equities analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a stock buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to buy up to 3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Activity

In other news, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the sale, the insider directly owned 6,175 shares of the company’s stock, valued at $226,684.25. This represents a 53.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78. Following the sale, the chief financial officer owned 91,617 shares of the company’s stock, valued at approximately $2,779,659.78. This represents a 9.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 82,963 shares of company stock worth $2,944,621. 17.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after acquiring an additional 1,407,651 shares during the period. Capital World Investors grew its holdings in Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after buying an additional 223,892 shares in the last quarter. Farallon Capital Management LLC increased its position in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the period. State Street Corp boosted its position in shares of Hims & Hers Health by 1.8% in the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after acquiring an additional 132,311 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after acquiring an additional 608,950 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Q4 EPS and profitability beat expectations, showing improving unit economics and a return to positive EPS. This supports HIMS’ longer‑term profitability story. Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall
Positive Sentiment: FY‑2026 revenue guidance of $2.7B–$2.9B came in at or above street estimates, and management is accelerating international expansion and new specialty launches — a potential top‑line growth driver. Hims & Hers projects $2.7B–$2.9B revenue in 2026 while accelerating global expansion and new specialty launches
Positive Sentiment: Acquisition of Eucalyptus (deal up to ~$1.15B) expands HIMS’ global footprint and subscription base — strategic M&A that could lift long‑term revenue and margins if integration succeeds. Hims & Hers Health, Inc. Expands Global Footprint With Eucalyptus Acquisition
Neutral Sentiment: Company highlights record subscriber growth and strategic investments in tech and international markets on the earnings call; these are supportive but increase near‑term spend. Hims & Hers Health Inc (HIMS) Q4 2025 Earnings Call Highlights
Neutral Sentiment: Reuters and other outlets note HIMS forecasted 2026 revenue above estimates overall, but the company guided Q1 below consensus — leaving investors split between full‑year potential and near‑term weakness. Hims & Hers forecasts 2026 revenue above estimates
Negative Sentiment: Disclosed SEC inquiry into its “copycat” GLP‑1 compounding business raises regulatory and legal risk around HIMS’ core weight‑loss product line — a clear near‑term catalyst for selling pressure. Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls
Negative Sentiment: First‑quarter revenue guidance of $600M–$625M missed Street estimates (~$650M), and management warned of near‑term pressure as prices and compounding dynamics evolve — prompting the share selloff. Hims & Hers forecasts first-quarter sales below estimates, shares fall
Negative Sentiment: Investor concern that aggressive marketing (including a Super Bowl ad) and expansion spending could pressure near‑term profits despite growth ambitions. Hims & Hers’ expansion plans — as well as its Super Bowl ad — have investors worried about profits

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.